Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
47 Ergebnisse für "immunotherapies" unter Somagenetix
Development of a novel class of interleukin-2 immunotherapies for m...
... immunotherapies for metastatic cancer. Swiss Medical Weekly, 149:w14697. Copy Abstract Tumour immunotherapy, and ... Development of a novel class of interleukin-2 immunotherapies for metastatic cancer - Zurich Open ... Development of a novel class of interleukin-2 immunotherapies for metastatic cancer - Zurich Open ... Development of a novel class of interleukin-2 immunotherapies for metastatic cancer - Zurich Open ...
Emerging immunotargets and immunotherapies in prostate cancer - Zur...
... Emerging immunotargets and immunotherapies in prostate cancer - Zurich Open Repository and Archive ... Emerging immunotargets and immunotherapies in prostate cancer - Zurich Open Repository and Archive ... Emerging immunotargets and immunotherapies in prostate cancer - Zurich Open Repository and Archive ...
ImmunOs Therapeutics AG
http://immunostherapeutics.com/
8952 Schlieren, Wagistrasse 14
ImmunOs Therapeutics AG is a clinical-stage biotechnology company developing the next generation of novel immunotherapies that enhance the efficacy of market leading checkpoint inhibitors and costimulatory agonists for cancer therapy. The company is actively discussing and exploring new strategic collaborations with leading global pharmaceutical companies.
ImmunOs Therapeutics AG
Wagistrasse 14
8952 Schlieren
10 Ergebnisse für "immunotherapies" unter ImmunOs Therapeutics AG
ENGAGING THE ENTIRE IMMUNE SYSTEM TO FIGHT DISEASE - Immunostherapy
... generation of novel immunotherapies that will improve the lives of patients with serious diseases. ... generation of novel immunotherapies that will improve the lives of patients with serious diseases. LeaRN More ... PIPELINE ImmunOs’ HLA-based pipeline includes first-in-class immunotherapies for the treatment of cancer ...
CDR-Life AG
8810 Horgen, Tödistrasse 46
CDR-Life is a Zurich-based biotech company that discovers and develops innovative medicines for the treatment of high need diseases. We invent and develop therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology.
CDR-Life AG
Tödistrasse 46
8810 Horgen
8 Ergebnisse für "immunotherapies" unter CDR-Life AG
... of novel immunotherapies in patient biopsies ZURICH, Switzerland, May 23, 2018 – CDR-Life inc. has ... technology. The collaboration will use synergies between the modular multispecific immunotherapies from CDR ... of novel immunotherapies in patient biopsies ZURICH, Switzerland, May 23, 2018 – CDR-Life inc. has ... technology. The collaboration will use synergies between the modular multispecific immunotherapies from CDR ...
News – CDR-Life
... ETH Zürich Ex vivo drug response profiling of novel immunotherapies in patient biopsies Download Press ... will use synergies between the modular multispecific immunotherapies from CDR-Life and the ... profiling of novel immunotherapies in patient biopsies Download Press Release (PDF) ZURICH, Switzerland, May ... modular multispecific immunotherapies from CDR-Life and the pharmacoscopy technology from the Snijder ...
Virometix AG
8952 Schlieren, Wagistrasse 14
+41 (0)43 433 86 60
info@virometix.com
Virometix AG is a privately held biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.
Virometix AG
Wagistrasse 14
8952 Schlieren
4 Ergebnisse für "immunotherapies" unter Virometix AG
... , Switzerland, towards the evaluation of nanoparticle-based cancer vaccines and immunotherapies ... vaccine targets and immunotherapies • Mammalian cell culture and experience with cancer cell lines ... , Switzerland, towards the evaluation of nanoparticle-based cancer vaccines and immunotherapies ... vaccine targets and immunotherapies • Mammalian cell culture and experience with cancer cell lines ...
... evaluation of nanoparticle-based cancer vaccines and immunotherapies as part of a bigger team of biologists ... tests and experiments for the functional validation of novel cancer vaccine targets and immunotherapies ... evaluation of nanoparticle-based cancer vaccines and immunotherapies as part of a bigger team of biologists ... tests and experiments for the functional validation of novel cancer vaccine targets and immunotherapies ...
Repertoire Immune Medicines (Switzerland) AG
8952 Schlieren, Wagistrasse 27
The key to our strategy lies in understanding the inner workings of the immune synapse – the interaction between the T cell and the antigen presenting cell which dictates the immune code that tells a T cell to become toxic and to kill the infected tissue. Our scientists created and developed the DECODETM and DEPLOY suite of technologies, which allows in-depth characterization of TCR-antigen pairings – and the ability to rationally design and clinically develop targeted immune medicines. Our scientists also have developed novel technologies that attach potent immunomodulators to T cells, enabling us to deliver potent cytokines such as IL-15 or IL-12 directly to tumors by using the natural homing power of the T cells to traffic to diseased tissue.
Repertoire Immune Medicines (Switzerland) AG
Wagistrasse 27
8952 Schlieren
1 Ergebnisse für "immunotherapies" unter Repertoire Immune Medicines (Switzerland) AG
Jan Kisielow, PhD • Repertoire Immune Medicines
... provide the basis for personalized immunotherapies. He earned his PhD in cell biology from the Basel ... antigenic reactivity of T cells to provide the basis for personalized immunotherapies. He earned his PhD in ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
29 Ergebnisse für "immunotherapies" unter University of Zurich
UZH - UZH Innovation Hub - UZH spin-off Anaveon successfully closed...
... . based in the a UK. Anaveon works on a new approach for developing immunotherapies for cancer. The ... approach for developing immunotherapies for cancer. The technology was developed by Prof. Onur Boyman. The ...
UZH - Institute for Regenerative Medicine • IREM - Antibody-based R...
... immunotherapies for neurodegenerative diseases, including Aducanumab resulting from research conducted at the ... Regeneration With the advent of clinically effective immunotherapies for neurodegenerative diseases, including ...
Roche Glycart AG
https://www.roche.ch/en/sites/schlieren
8952 Schlieren, Wagistrasse 10
+41 43 215 10 00
The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.
Roche Glycart AG
Wagistrasse 10
8952 Schlieren
28 Ergebnisse für "immunotherapies" unter Roche Glycart AG
Roche | Ovarian cancer treatment advances over time – what’s next?
... . The introduction of immunotherapies, and combinations of immunotherapies with other targeted therapies ... to see in the treatment of this deadly cancer. The introduction of immunotherapies, and combinations ... of immunotherapies with other targeted therapies, are also expected to come through in this disease ...
Roche - Immunotherapy at Roche
... . Cancer immunotherapies of the past In fact, the idea of harnessing the immune system to fight cancer is a ... generate positive results. Unlike earlier immunotherapies, these drugs work by targeting a specific set of ... . Cancer immunotherapies of the past In fact, the idea of harnessing the immune system to fight cancer is a ... generate positive results. Unlike earlier immunotherapies, these drugs work by targeting a specific set of ...
Bio-Technopark Schlieren-Zürich
8952 Schlieren, Wagistrasse 23
+41 76 336 99 44
mario.jenni@bio-technopark.ch
The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.
Bio-Technopark Schlieren-Zürich
Wagistrasse 23
8952 Schlieren
6 Ergebnisse für "immunotherapies" unter Bio-Technopark Schlieren-Zürich
Kuros Biosciences’s licensee Checkmate Pharmaceuticals completes it...
... -001 across multiple tumor types in combination with several checkpoint inhibitor immunotherapies. CMP ... immunotherapies. CMP-001 was licensed from Kuros Biosciences in 2015. Under the 2015 license agreement, Kuros ...
CDR-Life Announces $76 Million Raised in Series A Funding › BIO-TEC...
... continuing development of novel targeted immunotherapies based on CDR-Life’s superior T cell engaging ... pipeline and goal of empowering cancer patients with uniquely targeted immunotherapies.” “We are thrilled ... development of novel targeted immunotherapies based on CDR-Life’s superior T cell engaging platform. We are ... empowering cancer patients with uniquely targeted immunotherapies.” “We are thrilled to invest in CDR-Life ...
ETH Entrepreneurship
https://ethz.ch/en/industry/entrepreneurship.html
8952 Schlieren, Wagistrasse 18
Excellence in entrepreneurship at ETH Zurich is driven by world-class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions.
ETH Entrepreneurship
Wagistrasse 18
8952 Schlieren
1 Ergebnisse für "immunotherapies" unter ETH Entrepreneurship
The solid tumor microenvironment-Breaking the barrier for T cells H...
... novel adoptive tumor immunotherapies. Show more External links ... and their effects on T cells is key for developing novel adoptive tumor immunotherapies. Show more ...
University Hospital Zurich, Research and Education Office
https://www.usz.ch/forschung/Seiten/default.aspx
8091 Zürich, Rämistrasse 100
The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.
University Hospital Zurich, Research and Education Office
Rämistrasse 100
8091 Zürich
17 Ergebnisse für "immunotherapies" unter University Hospital Zurich, Research and Education Office
Cancer Research Areas & Groups – USZ
... immunotherapies with minimal side effects. Learn more Many of the characteristics of cancer cells, such as ... tumor and immune system. The overall aim is to develop novel immunotherapies with minimal side effects ...
Programm_Symposium Immunotherapy_A5.indd
... immunotherapies Tumour immunology, Maries van den Broek Immunomonitoring, Bernd Bodenmiller Immune checkpoints ... immunotherapies Tumour immunology, Maries van den Broek Immunomonitoring, Bernd Bodenmiller Immune checkpoints ...